Entera Market Capitalization from 2010 to 2024
| ENTX Stock | USD 1.59 0.03 1.85% |
Check Entera Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Entera Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 97.3 K, Interest Expense of 31.4 M or Selling General Administrative of 5.2 M, as well as many indicators such as Price To Sales Ratio of 79.86, Dividend Yield of 0.0 or PTB Ratio of 1.76. Entera financial statements analysis is a perfect complement when working with Entera Bio Valuation or Volatility modules.
Entera | Market Capitalization |
Latest Entera Bio's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Entera Bio over the last few years. It is Entera Bio's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Entera Bio's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 58.56 M | 10 Years Trend |
|
Market Cap |
| Timeline |
Entera Market Capitalization Regression Statistics
| Arithmetic Mean | 50,319,005 | |
| Geometric Mean | 42,661,153 | |
| Coefficient Of Variation | 51.55 | |
| Mean Deviation | 23,572,858 | |
| Median | 53,840,895 | |
| Standard Deviation | 25,941,309 | |
| Sample Variance | 673T | |
| Range | 58.2M | |
| R-Value | (0.81) | |
| Mean Square Error | 249.6T | |
| R-Squared | 0.66 | |
| Significance | 0.0003 | |
| Slope | (4,696,814) | |
| Total Sum of Squares | 9421.3T |
Entera Market Capitalization History
About Entera Bio Financial Statements
Entera Bio investors use historical fundamental indicators, such as Entera Bio's Market Capitalization, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Entera Bio. Please read more on our technical analysis and fundamental analysis pages.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.